S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

OrthoPediatrics Corp. (NASDAQ:KIDS) Expected to Post Quarterly Sales of $25.06 Million

Sunday, January 2, 2022 | MarketBeat

Analysts expect OrthoPediatrics Corp. (NASDAQ:KIDS) to announce $25.06 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for OrthoPediatrics' earnings, with the highest sales estimate coming in at $25.61 million and the lowest estimate coming in at $24.76 million. OrthoPediatrics reported sales of $18.92 million in the same quarter last year, which indicates a positive year-over-year growth rate of 32.5%. The company is scheduled to report its next earnings report on Wednesday, March 9th.

According to Zacks, analysts expect that OrthoPediatrics will report full year sales of $98.28 million for the current fiscal year, with estimates ranging from $97.99 million to $98.84 million. For the next financial year, analysts anticipate that the firm will report sales of $121.03 million, with estimates ranging from $118.84 million to $125.20 million. Zacks Investment Research's sales calculations are an average based on a survey of sell-side analysts that that provide coverage for OrthoPediatrics.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Wednesday, November 3rd. The company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.13. The company had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative net margin of 32.93% and a negative return on equity of 7.10%.

KIDS has been the subject of several research analyst reports. Truist Securities reduced their target price on shares of OrthoPediatrics from $78.00 to $75.00 and set a "buy" rating for the company in a report on Tuesday, December 21st. Zacks Investment Research cut shares of OrthoPediatrics from a "buy" rating to a "hold" rating in a research report on Wednesday, October 6th. Finally, BTIG Research dropped their target price on shares of OrthoPediatrics from $75.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, December 22nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $75.14.

Shares of KIDS stock opened at $59.86 on Friday. OrthoPediatrics has a 1 year low of $38.83 and a 1 year high of $73.91. The firm's fifty day moving average price is $61.78 and its two-hundred day moving average price is $63.55. The firm has a market capitalization of $1.18 billion, a P/E ratio of -38.13 and a beta of 0.77.

In other news, major shareholder Jennifer N. Pritzker acquired 1,000 shares of the business's stock in a transaction dated Thursday, December 9th. The stock was bought at an average cost of $60.42 per share, for a total transaction of $60,420.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 30.30% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Stifel Financial Corp raised its stake in OrthoPediatrics by 1.7% in the second quarter. Stifel Financial Corp now owns 10,740 shares of the company's stock valued at $679,000 after purchasing an additional 180 shares in the last quarter. UBS Group AG raised its stake in OrthoPediatrics by 106.4% in the third quarter. UBS Group AG now owns 421 shares of the company's stock valued at $28,000 after purchasing an additional 217 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in OrthoPediatrics by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 7,993 shares of the company's stock valued at $505,000 after purchasing an additional 227 shares in the last quarter. Tudor Investment Corp Et Al raised its stake in OrthoPediatrics by 2.2% in the third quarter. Tudor Investment Corp Et Al now owns 10,522 shares of the company's stock valued at $689,000 after purchasing an additional 230 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in OrthoPediatrics by 8.3% in the second quarter. SG Americas Securities LLC now owns 3,088 shares of the company's stock valued at $195,000 after purchasing an additional 236 shares in the last quarter. Institutional investors own 76.34% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard.

Recommended Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in OrthoPediatrics right now?

Before you consider OrthoPediatrics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.

While OrthoPediatrics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.